Lymphoma, Large-Cell, Anaplastic clinical trials

The registry lists 397 studies for Lymphoma, Large-Cell, Anaplastic across more than 10 countries. 26 are recruiting or about to start. 80 of them are mainly about Lymphoma, Large-Cell, Anaplastic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Lymphoma, Large-Cell, Anaplastic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 255
Terminated: 57
Status unknown: 21
Withdrawn: 21
Recruiting: 21
Active, not recruiting: 12

Phase

Phase 1: 188
Phase 2: 153
Phase 3: 32
Phase 4: 5
Early Phase 1: 4

Where

United States: 311
Italy: 32
Canada: 26
France: 26
Germany: 23
United Kingdom: 21

Who runs them

National Cancer Institute (NCI) (58) · Fred Hutchinson Cancer Center (22) · Memorial Sloan Kettering Cancer Center (15) · City of Hope Medical Center (15) · Mayo Clinic (13) · Case Comprehensive Cancer Center (11) · M.D. Anderson Cancer Center (11) · Seagen Inc. (11)

What is being tested here

Drugs under test in Lymphoma, Large-Cell, Anaplastic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cyclophosphamide	2	4	28
Azacitidine	2	0	5
Alectinib	2	1	3
Cemiplimab	2	0	2
Fludarabine	1	1	22
Brentuximab Vedotin	1	1	20
Prednisone	1	2	9
Vincristine	1	3	9
Pralatrexate	1	0	5
Nivolumab	1	0	4

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · Antimetabolites 3 open · Alkylating agents 3 open · Immune checkpoint inhibitors 3 open · Antimitotic agents 1 open

Coming up

4phase 3 studies under way

5studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Nov 2027Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · Phase 3 · Corvus Pharmaceuticals, Inc.
Mar 2027Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · National Cancer Institute (NCI)
Apr 2027Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies · Fred Hutchinson Cancer Center
Jun 2027Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) · Hoffmann-La Roche
Sep 2027Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · National Cancer Institute (NCI)

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger. 8 (38%) take children under 18. 1 (5%) are for women only and 0 (0%) for men only; 1 (5%) take healthy volunteers.

Recruiting studies that take each age, of 21
Age	Women	Men
10	7 (33%)	7 (33%)
18	20 (95%)	19 (90%)
30	18 (86%)	17 (81%)
40	17 (81%)	16 (76%)
50	17 (81%)	16 (76%)
65	18 (86%)	17 (81%)
75	18 (86%)	17 (81%)
85	14 (67%)	13 (62%)

Across all 397 studies, recruiting or not: 27% stop at 75 or younger and 17% at 65; 32% take children; 1% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Large-Cell, Anaplastic studies take

Of 33 phase 2 interventional studies under Lymphoma, Large-Cell, Anaplastic, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	64 mo39–80 · 31 studies	—	—
Phase 1/2	71 mo49–92 · 15 studies	—	—
Phase 2	64 mo43–97 · 33 studies	—	64 mo45–97 · 29 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaOct 30, 2026NCT07691450

Studies

Recruiting first, then most recently updated. Showing 50 of 397. Browse all 397 → or search them.